BridgeBio Pharma Inc

NASDAQ:BBIO   3:59:55 PM EDT
9.08
+0.24 (+2.72%)
Products, Regulatory, Earnings Announcements

Bridgebio Pharma Affiliate Announces Positive Results From Phase 2 Trial Of PTR-01 For Treatment Of Recessive Dystrophic Epidermolysis Bullosa

Published: 05/20/2022 13:15 GMT
BridgeBio Pharma Inc (BBIO) - Bridgebio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results From Phase 2 Trial of Ptr-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (rdeb).
Bridgebio Pharma Inc - Ptr-01 Was Well-tolerated Over a Four-month Treatment Period in Rdeb Patients.
Bridgebio Pharma Inc - All Patients That Completed Study Reported a Decrease in Pain Over Course of Treatment With Ptr-01.
Bridgebio Pharma Inc - Phoenix Tissue Repair Has Initiated a Phase 2 Extension Study.
Revenue is expected to be $41.92 Million
Adjusted EPS is expected to be -$0.60

Next Quarter Revenue Guidance is expected to be $19.16 Million
Next Quarter EPS Guidance is expected to be -$0.86

More details on our Analysts Page.